How to translate clinical trial results into gain in healthy life expectancy for individual patients
Abstract
Treatment effects from randomised trials are typically expressed as numbers needed to treat to prevent one adverse disease event during a fixed time interval (eg, five or 10 years). In the actual patient, however, many diseases are chronically progressive, despite treatment. Examples are diabetic nephropathy, some types of malignancies, osteoporosis, and atherosclerosis. In these examples, the aim of treatment is not to prevent but to delay the occurrence of symptomatic disease. Thus the actual effect of treatment is gain in disease-free life expectancyKeywords
This publication has 18 references indexed in Scilit:
- Personalized Prediction of Lifetime Benefits with Statin Therapy for Asymptomatic Individuals: A Modeling StudyPLOS Medicine, 2012
- Development and Validation of a Coronary Risk Prediction Model for Older U.S. and European Persons in the Cardiovascular Health Study and the Rotterdam StudyAnnals of Internal Medicine, 2012
- European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) * Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)European Heart Journal, 2012
- Aspirin for primary prevention of vascular events in women: individualized prediction of treatment effectsEuropean Heart Journal, 2011
- Competing risks and the clinical community: irrelevance or ignorance?Statistics in Medicine, 2011
- Derivation, validation, and evaluation of a new QRISK model to estimate lifetime risk of cardiovascular disease: cohort study using QResearch databaseBMJ, 2010
- Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trialsThe Lancet, 2009
- Prediction of Recurrence-Free Survival in Postoperative Non–Small Cell Lung Cancer Patients by Using an Integrated Model of Clinical Information and Gene ExpressionClinical Cancer Research, 2008
- Competing risk and heterogeneity of treatment effect in clinical trialsTrials, 2008
- General Cardiovascular Risk Profile for Use in Primary CareCirculation, 2008